Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

MoonLake Immunotherapeutics

35 indications, side-by-side phase, drug & LoA

$18.69

+0.9 (+5.07%)

C 42Pipeline Score Richly Valued Pharma · Clinical
Market Cap
1.34 B
EPS
-3.87
P/E Ratio
-
Value Trade
10.42 M
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • R&D Expenses

    54.52 M

  • Operating CF

    -66.29 M

  • Total Assets

    400.37 M

  • Total Liabilities

    146.35 M

  • Equity

    254.02 M

  • D/E Ratio

    12,345

-0.38 %
Week
4.12 %
1 Month
1.17 %
3 Month
39.92 %
6 Month
82.81 %
5 Year
79.04 %
All Time
Cash Data
Stable

  • Cash Position

    357.92 M

  • Monthly Burn

    22.09 M

  • Runway

    15.2 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 11, 2026
Overview
Volume
738.57 K
52 Week Range
5.95 - 62.75
% held by Insiders
13.99 %
% held by Institutions
82.08 %
Enterprise Value
1.08 B
Total Shares
71.67 M
Short %
12.67 %
Float Shares
43.93 M
Company Description
HQ: DORFSTRASSE 29, ZUG, V8, 6300
Employees:130
https://www.moonlaketx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout example
sonelokimab (SLK) Axial spondyloarthritis (axSpA)
Phase 2
—
-
-
sonelokimab (SLK) Axial spondyloarthritis (axSpA)
Phase 2
—
-
-
sonelokimab (SLK) Axial spondyloarthritis (axSpA)
Phase 2
—
-
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C42
Pipeline Score
$104M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 56%
Micro Cap
(rank 399 of 905)
Percentile Rank
MoonLake Immunotherapeutics carries a moderate pipeline score (42/100), with $260M risk-adjusted pipeline value, led by Sonelokimab in Arthritis, Psoriatic (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Sonelokimab
Small molecule		Hidradenitis SuppurativaPhase 3NCT0641137958% $260M COMPLETED 1,944 VERY_FAST B (67) May 20, 2026LOW_RISKHIGH
Jun 8, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
sonelokimab
hidradenitis suppurativa,palmoplantar pustulosis,axial spondyloarthritis,psoriatic arthritis
Phase 3
2025-08-06
sonelokimab
hidradenitis suppurativa,palmoplantar pustulosis,axial spondyloarthritis,psoriatic arthritis
Phase 3
2025-08-06
sonelokimab
hidradenitis suppurativa,palmoplantar pustulosis,axial spondyloarthritis,psoriatic arthritis
Phase 3
2025-08-06
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in MLTX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MLTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MLTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MLTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
MLTX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
MLTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest MoonLake Immunotherapeutics (MLTX) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How MLTX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Hidradenitis Suppurativa #4 of 13 PHASE 3 Sonelokimab
ABBV INCY NVS
$1.7B 0.98 CONTENDER
Psoriatic Arthritis #5 of 13 PHASE 3 Sonelokimab
JNJ ABBV BMY
—0.98 CONTENDER